281 related articles for article (PubMed ID: 34093551)
1. A Sensitive Whole Blood Assay Detects Antigen-Stimulated Cytokine Release From CD4+ T Cells and Facilitates Immunomonitoring in a Phase 2 Clinical Trial of Nexvax2 in Coeliac Disease.
Hardy MY; Goel G; Russell AK; Chen Yi Mei SLG; Brown GJE; Wang S; Szymczak E; Zhang R; Goldstein KE; Neff KM; Williams LJ; Truitt KE; Dzuris JL; Tye-Din JA; Anderson RP
Front Immunol; 2021; 12():661622. PubMed ID: 34093551
[TBL] [Abstract][Full Text] [Related]
2. Whole blood interleukin-2 release test to detect and characterize rare circulating gluten-specific T cell responses in coeliac disease.
Anderson RP; Goel G; Hardy MY; Russell AK; Wang S; Szymczak E; Zhang R; Goldstein KE; Neff K; Truitt KE; Williams LJ; Dzuris JL; Tye-Din JA
Clin Exp Immunol; 2021 Jun; 204(3):321-334. PubMed ID: 33469922
[TBL] [Abstract][Full Text] [Related]
3. Epitope-specific immunotherapy targeting CD4-positive T cells in coeliac disease: two randomised, double-blind, placebo-controlled phase 1 studies.
Goel G; King T; Daveson AJ; Andrews JM; Krishnarajah J; Krause R; Brown GJE; Fogel R; Barish CF; Epstein R; Kinney TP; Miner PB; Tye-Din JA; Girardin A; Taavela J; Popp A; Sidney J; Mäki M; Goldstein KE; Griffin PH; Wang S; Dzuris JL; Williams LJ; Sette A; Xavier RJ; Sollid LM; Jabri B; Anderson RP
Lancet Gastroenterol Hepatol; 2017 Jul; 2(7):479-493. PubMed ID: 28506538
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of gluten peptide-based antigen-specific immunotherapy (Nexvax2) in adults with coeliac disease after bolus exposure to gluten (RESET CeD): an interim analysis of a terminated randomised, double-blind, placebo-controlled phase 2 study.
Tye-Din JA; Daveson AJM; Goel G; Goldstein KE; Hand HL; Neff KM; Popp A; Taavela J; Maki M; Isola J; Williams LJ; Truitt KE; Anderson RP;
Lancet Gastroenterol Hepatol; 2023 May; 8(5):446-457. PubMed ID: 36898393
[TBL] [Abstract][Full Text] [Related]
5. Epitope-Specific Immunotherapy Targeting CD4-Positive T Cells in Celiac Disease: Safety, Pharmacokinetics, and Effects on Intestinal Histology and Plasma Cytokines with Escalating Dose Regimens of Nexvax2 in a Randomized, Double-Blind, Placebo-Controlled Phase 1 Study.
Daveson AJM; Ee HC; Andrews JM; King T; Goldstein KE; Dzuris JL; MacDougall JA; Williams LJ; Treohan A; Cooreman MP; Anderson RP
EBioMedicine; 2017 Dec; 26():78-90. PubMed ID: 29191561
[TBL] [Abstract][Full Text] [Related]
6. Ex-vivo whole blood secretion of interferon (IFN)-γ and IFN-γ-inducible protein-10 measured by enzyme-linked immunosorbent assay are as sensitive as IFN-γ enzyme-linked immunospot for the detection of gluten-reactive T cells in human leucocyte antigen (HLA)-DQ2·5(+) -associated coeliac disease.
Ontiveros N; Tye-Din JA; Hardy MY; Anderson RP
Clin Exp Immunol; 2014 Feb; 175(2):305-15. PubMed ID: 24192268
[TBL] [Abstract][Full Text] [Related]
7. Serum cytokines elevated during gluten-mediated cytokine release in coeliac disease.
Goel G; Daveson AJM; Hooi CE; Tye-Din JA; Wang S; Szymczak E; Williams LJ; Dzuris JL; Neff KM; Truitt KE; Anderson RP
Clin Exp Immunol; 2020 Jan; 199(1):68-78. PubMed ID: 31505020
[TBL] [Abstract][Full Text] [Related]
8. T cells in peripheral blood after gluten challenge in coeliac disease.
Anderson RP; van Heel DA; Tye-Din JA; Barnardo M; Salio M; Jewell DP; Hill AV
Gut; 2005 Sep; 54(9):1217-23. PubMed ID: 16099789
[TBL] [Abstract][Full Text] [Related]
9. Cytokine release after gluten ingestion differentiates coeliac disease from self-reported gluten sensitivity.
Tye-Din JA; Skodje GI; Sarna VK; Dzuris JL; Russell AK; Goel G; Wang S; Goldstein KE; Williams LJ; Sollid LM; Lundin KE; Anderson RP
United European Gastroenterol J; 2020 Feb; 8(1):108-118. PubMed ID: 32213060
[TBL] [Abstract][Full Text] [Related]
10. A bispecific antibody targeting HLA-DQ2.5-gluten peptides potently blocks gluten-specific T cells induced by gluten ingestion in patients with celiac disease.
Hardy MY; Henneken LM; Russell AK; Okura Y; Mizoroki A; Ozono Y; Kobayashi S; Murakami Y; Tye-Din JA
Clin Immunol; 2024 Jul; 264():110259. PubMed ID: 38768856
[TBL] [Abstract][Full Text] [Related]
11. Antagonists and non-toxic variants of the dominant wheat gliadin T cell epitope in coeliac disease.
Anderson RP; van Heel DA; Tye-Din JA; Jewell DP; Hill AV
Gut; 2006 Apr; 55(4):485-91. PubMed ID: 16299041
[TBL] [Abstract][Full Text] [Related]
12. CD38 expression on gluten-specific T cells is a robust marker of gluten re-exposure in coeliac disease.
Zühlke S; Risnes LF; Dahal-Koirala S; Christophersen A; Sollid LM; Lundin KE
United European Gastroenterol J; 2019 Dec; 7(10):1337-1344. PubMed ID: 31839959
[TBL] [Abstract][Full Text] [Related]
13. HLA-DQ:gluten tetramer test in blood gives better detection of coeliac patients than biopsy after 14-day gluten challenge.
Sarna VK; Skodje GI; Reims HM; Risnes LF; Dahal-Koirala S; Sollid LM; Lundin KEA
Gut; 2018 Sep; 67(9):1606-1613. PubMed ID: 28779027
[TBL] [Abstract][Full Text] [Related]
14. Cytokine release and gastrointestinal symptoms after gluten challenge in celiac disease.
Goel G; Tye-Din JA; Qiao SW; Russell AK; Mayassi T; Ciszewski C; Sarna VK; Wang S; Goldstein KE; Dzuris JL; Williams LJ; Xavier RJ; Lundin KEA; Jabri B; Sollid LM; Anderson RP
Sci Adv; 2019 Aug; 5(8):eaaw7756. PubMed ID: 31457091
[TBL] [Abstract][Full Text] [Related]
15. HLA-DQ2-restricted gluten-reactive T cells produce IL-21 but not IL-17 or IL-22.
Bodd M; Ráki M; Tollefsen S; Fallang LE; Bergseng E; Lundin KE; Sollid LM
Mucosal Immunol; 2010 Nov; 3(6):594-601. PubMed ID: 20571486
[TBL] [Abstract][Full Text] [Related]
16. Short wheat challenge is a reproducible in-vivo assay to detect immune response to gluten.
Camarca A; Radano G; Di Mase R; Terrone G; Maurano F; Auricchio S; Troncone R; Greco L; Gianfrani C
Clin Exp Immunol; 2012 Aug; 169(2):129-36. PubMed ID: 22774987
[TBL] [Abstract][Full Text] [Related]
17. Evaluating Responses to Gluten Challenge: A Randomized, Double-Blind, 2-Dose Gluten Challenge Trial.
Leonard MM; Silvester JA; Leffler D; Fasano A; Kelly CP; Lewis SK; Goldsmith JD; Greenblatt E; Kwok WW; McAuliffe WJ; Galinsky K; Siegelman J; Chow IT; Wagner JA; Sapone A; Smithson G
Gastroenterology; 2021 Feb; 160(3):720-733.e8. PubMed ID: 33130104
[TBL] [Abstract][Full Text] [Related]
18. Circulating gluten-specific FOXP3
Cook L; Munier CML; Seddiki N; van Bockel D; Ontiveros N; Hardy MY; Gillies JK; Levings MK; Reid HH; Petersen J; Rossjohn J; Anderson RP; Zaunders JJ; Tye-Din JA; Kelleher AD
J Allergy Clin Immunol; 2017 Dec; 140(6):1592-1603.e8. PubMed ID: 28283419
[TBL] [Abstract][Full Text] [Related]
19. Pathogenic T Cells in Celiac Disease Change Phenotype on Gluten Challenge: Implications for T-Cell-Directed Therapies.
Christophersen A; Zühlke S; Lund EG; Snir O; Dahal-Koirala S; Risnes LF; Jahnsen J; Lundin KEA; Sollid LM
Adv Sci (Weinh); 2021 Nov; 8(21):e2102778. PubMed ID: 34495570
[TBL] [Abstract][Full Text] [Related]
20. Gluten specific, HLA-DQ restricted T cells from coeliac mucosa produce cytokines with Th1 or Th0 profile dominated by interferon gamma.
Nilsen EM; Lundin KE; Krajci P; Scott H; Sollid LM; Brandtzaeg P
Gut; 1995 Dec; 37(6):766-76. PubMed ID: 8537046
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
